Sep 15, 2015 by Brian FeroldiBetter Buy: T. Rowe Price Health Sciences vs. Vanguard Health Care Fund Investor SharesWhich is the better choice for new money?
Sep 14, 2015 by Brian Feroldi, Todd Campbell, and George Budwell, PhDBetter Buy: Biogen vs. Gilead SciencesThe recent market turmoil has put both of these biotech blue chips in the discount pile. Which stock do our Motley Fool contributors think is the better buy today?
Sep 14, 2015 by Brian Feroldi, Selena Maranjian, and Brian Stoffel3 Critical Points to Consider When Selecting a Mutual FundInteresting in investing in a mutual fund? Make sure you keep these key points in mind.
Sep 14, 2015 by Brian Feroldi, Todd Campbell, George Budwell, PhD, and Cheryl SwansonWhich Biotech Blue-Chip Stock Is the Best Buy?When the markets get messy, we like to go bargain hunting for the best stocks we can find. So, which biotech stocks do our contributors think are great buys right now?
Sep 14, 2015 by Brian Feroldi, Daniel Miller, Bob Ciura, Todd Campbell, and Adam Galas5 Great Stocks on SaleWhen the market goes down, many great names can suddenly find themselves on sale. Here are a few names that our contributors think investors should consider.
Sep 13, 2015 by Brian Feroldi, Selena Maranjian, Todd Campbell, and George Budwell, PhD4 Ways to Protect Yourself From a Biotech MeltdownWhen markets head south, biotech stocks tend to get hit hard. Here are four ideas that you can use to keep your investments safe in the mayhem.
Sep 13, 2015 by Brian Feroldi, Todd Campbell, and George Budwell, PhDIs It Time to Kick These Healthcare Laggards Out of Your Portfolio?The time may be right to give these 3 healthcare stocks the boot.
Sep 12, 2015 by Brian FeroldiWhy Shares of Halozyme Therapeutics Inc. Plunged 24% in AugustMr. Market sends shares lower after the company reports good news. Could this be a buying opportunity?
Sep 12, 2015 by Brian FeroldiThese 3 Numbers Say Amgen Inc. Is CheapIs it time to buy in to this beaten-down blue chip?
Sep 11, 2015 by Brian FeroldiWhy Shares of Keryx Biopharmaceuticals Dropped Hard in AugustDisappointing sales results cause analysts to turn bearish, driving shares lower.
Sep 11, 2015 by Brian FeroldiBetter Buy: Amgen, Inc or Regeneron Pharmaceuticals Inc?With both of these companies scoring blockbuster FDA approvals in the past month, which is the better choice for your investing dollar?
Sep 11, 2015 by Brian FeroldiWhy MannKind Corporation Fell 11% in AugustDisappointing quarterly results continue to put selling pressure on the stock.
Sep 11, 2015 by Brian FeroldiWhy Castlight Health Sank Another 25% in AugustCastlight Health continues to be a poor investment, but could we be finally reaching a bottom?
Sep 10, 2015 by Brian FeroldiWhy Shares of AbbVie Inc. Dropped 10% in AugustGreat second-quarter results couldn't save the stock from Mr. Market's August temper tantrum.
Sep 9, 2015 by Brian FeroldiAttention Biotech Investors: Biosimilars Are Finally Here!Novartis is now cleared to sell the first-ever biosimilar drug in the U.S., but who are the winners and losers in this sea of change?
Sep 9, 2015 by Brian FeroldiWhy Clovis Oncology Inc Shares Are Rocketing Higher TodayInvestor excitement continues to ramp for this long-time winner after the company presented updated clinic results at the World Conference on Lung Cancer.
Sep 9, 2015 by Brian FeroldiWhy Tetraphase Pharmaceuticals Inc Stock Was Annihilated TodayDisappointing news from a phase 3 clinical trial have investors fleeing for the exits.
Sep 8, 2015 by Brian FeroldiSPDR S&P Biotech ETF: A Closer LookLet's break down what this ETF offers investors.
Sep 7, 2015 by Brian Feroldi, Tim Brugger, Joe Tenebruso, and Adam GalasThe 4 Best Warren Buffett Stocks to Buy Right NowOur contributors pick through the Oracle of Omaha's portfolio to say which stocks are the best bets right now.
Sep 6, 2015 by Brian FeroldiThis Presidential Candidate is Big Pharma's Worst NightmarePresidential hopeful Bernie Sanders is introducing legislation to stop the escalation in pharmaceutical prices. What would its passage mean for big pharma companies?
